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gabapentin and pregabalin) in 2009. All selected patients had 12 months continu-
ous enrollment in the pre- and post-index periods, and were grouped into the
duloxetine or SOC cohort based on the index agent. The first dispense date was
defined as the index date, but with no use of the study medications in the prior 90
days. Both cohorts were then matched via propensity score. The propensity score
was estimated based on a logistic regressionmodel that predicted the likelihood of
initiating duloxetine adjusting for demographics, comorbidities, prior health care
utilization and costs, and priormedication history. Healthcare costs and opioid use
(those not initiated on opioids) over the 12-month post-index period were com-
pared between cohorts. RESULTS: The matched sample included 1517 patients in
both the duloxetine and SOC group. Both cohorts had a mean age of 54 years, and
were mostly females. Over the 12-month post index period, duloxetine-treated
patients had lower total health care costs than SOC-treated patients ($16,711 vs
$18,447, p0.05). They also had lower inpatient ($3,374 vs. $5,048) and outpatient
costs ($8,427 vs. $9,581), while the pharmacy costs were higher in duloxetine-
treated patients ($4,910 vs. $3,818) (all p0.05). In addition, duloxetine-treated pa-
tients were less likely to use any opioids (52% vs 63%, p0.05). CONCLUSIONS:
Commercially-insured OA patients initiating duloxetine were associated with sig-
nificantly lower health care costs and were less likely to use opioids. These results
should be interpreted with caution due to the observational nature of the claims
database.
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OBJECTIVES: To perform a cost analysis of using allopurinol or febuxostat (Uloric®)
as a first-line agent for the prophylaxis of gout.METHODS: The study was carried
out from the public payer perspective. Data was extracted from three published
Phase III clinical trials and other published data for input into a Markov model
developed using TreeAge Pro 2011©. Patient inclusion criteria were consistent with
the trials, including patients with baseline serum uric acid (sUA) concentration
greater than 9 mg/dL requiring prophylaxis therapy for gout. Direct medical costs
were assessed for patients starting either allopurinol 300mg/100mg, febuxostat 80mg,
or febuxostat 120mgperdayasfirst-line therapy. Cycle lengthof 1monthwasused for
a 5 year time horizon. The model was designed so that patients who did not achieve
therapeutic goals after 1 month of initial therapy can switch to other therapeutic
groups. Incidence of drugs achieving sUA goals  6mg/dL, costs of gout flares, and
costs of drugs themselves were included. Costs associated with adverse events were
not included in the model as adverse events were not significantly different between
therapeutic groups in published trials. All costs were converted to 2009 USD. Univar-
iate sensitivity analyses were performed on all input variables. RESULTS: Using allo-
purinol 300mg/100mg as first-line therapy showed a cost of $9,242.22 per patient
for five years. Conversely, strating febuxostat 80mg or 120mg showed higher costs
per patient at $11,616.79 and $14,499.79 over 5 years, respectively. Sensitivity anal-
yses show that the modeling results were robust. CONCLUSIONS: Over a 5 year
span of time, using allopurinol as the first-line therapy for prophylaxis of gouty
flares compared to febuxostat incur lower direct medical costs. This model, how-
ever, did not consider allopurinol dose escalation up to 900mg/day, which may
have underestimated cost savings for using allopurinol as the first-line therapy.
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OBJECTIVES: To estimate annual tumor necrosis factor (TNF)-blocker cost per
treated psoriatic arthritis (PsA) patient for etanercept, adalimumab, and infliximab
using drug utilization from a USmanaged care population.METHODS:MarketScan
Commercial Database was used to identify PsA patients, 18-64 years old, with 1
etanercept, adalimumab, or infliximab claim between November 1, 2005 and June
30, 2009. Patientswere continuously enrolled for 1 year after the initial TNF-blocker
claim (index). Sixmonths prior to index (pre-index period) was required to identify
new (no TNF-blocker claim) or continuing (had a TNF-blocker claim) patients. Pa-
tientswere excluded if they had other TNF-blocker-indicated conditions during the
pre-index period. Mean monthly dose was calculated for the three TNF-blockers
while patients were on therapy. 2011 wholesale acquisition costs were applied to
the mean monthly dose and the Medicare Physician Fee Schedule was applied to
related TNF-blocker administrations to estimate cost per treated patient.RESULTS:
Overall, 2,242 etanercept, 674 adalimumab, and 376 infliximab PsA patients were
included. Patient characteristicswere similar across treatment groupswith amean
age (SD) of 48 (10) years and 54% male. The annual TNF-blocker cost per treated
patient for all PsApatientswas $15,790 for etanercept, $18,031 for adalimumab, and
$26,973 for infliximab. The annual TNF-blocker cost per treated patient for new PsA
patients was $14,675 for etanercept, $17,133 for adalimumab, and $23,886 for inf-
liximab. For PsA patients continuing treatment, the annual TNF-blocker cost per
treated patientwas $16,195 for etanercept, $19,575 for adalimumab, and $28,663 for
infliximab. CONCLUSIONS: Based on actual drug utilization from a US managed
care population, TNF-blocker cost per treated PsA patient on adalimumab and
infliximabwere approximately 14%and 71%higher, respectively, thanTNF-blocker
cost per treated PsA patient on etanercept; patients on etanercept had the lowest
TNF-blocker cost per treated PsA patient.
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OBJECTIVES: To compare treatment costs of all anti-TNFa biologics treatments in
rheumatoid arthritis (RA), akylkosing spondilitis (AS) and psoriatic arthristis (PsA)
in the Brazilian public health care system. METHODS: In Brazil, four anti-TNFa
biologics are available for the treatment of RA, AS and PsA: adalimumab, etaner-
cept, infliximab, and golimumab. Yearly treatment costs were calculated for an
average patient of 70 kgs, considering dose and dosing intervals as defined in the
label for each drug. The price for adalimumab, etanercept and infliximabwas gath-
ered from the official government website for centralized purchasing, as these
drugs are already reimbursed for the three indications. The price of golimumabwas
defined according to law, based on the mandatory government discount of 24,38%
over the official list price. RESULTS: Golimumab has the lowest treatment cost
across the biologics in all indications, at R$ 21,471.94 per patient per year. This
treatment cost does not vary across indications or across years of treatment, as it does
not include a higher initial dose. Infliximab has the second lowest treatment followed
byadalimumabeat a cost ofR$29,280.00andR$36,374.00perpatient respectively.Due
to higher dosing of infliximab for AS and PsA, the average cost per patient is R$
37,820.00 similar to the yearly cost of adalimumab. Etanercept has the highest treat-
ment cost across all indications at R$ 44,800 per patient per year, with the highest
number of vials per patient per year.CONCLUSIONS:With the lowest treatment cost,
golimumab is an important treatment option for RA, AS and PsA. Given the high
expenditure of the Brazilian government with anti-TNFs, golimumabe can decrease
government expenditure between 27%-50%. Considering the total health care expen-
diture of R$ 1.67 million with adalimumab, etanercept and infliximab in the last 12
months, golimumab has the cost saving potential of about R$ 449 million.
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BACKGROUND: Information is limited regarding the costs associated with long
bone fractures in a working age population, particularly around lost productivity.
OBJECTIVES: To estimate the direct and indirect costs associated with long bone
fractures in a working age population. METHODS: Adult patients with long bone
fractures between 1/1/2001 and 12/31/2008were identified in theMarketScan Com-
mercial and Health Productivity Management Databases. Patient costs and utiliza-
tion, includingworkplace absenteeismand short termdisability, were compared in
the 6 months before and after a fracture. Observed incremental costs (i.e., the
difference in costs before and after a fracture) were reported in mutually exclusive
fracture cohorts. Multivariate adjusted costs were calculated using GLM with frac-
ture type as dummy variables. RESULTS: A total of 208,094 patients met the study
inclusion criteria for the following fracture types: tibia shaft (n49,839), radius
(n97,585), hip (n11,585), femur (n6,788), humerus (n29,884) and multiple
fractures (n12,413). The average observed direct costs in the 6-months prior to a
long bone fracture were as follows: radius ($3,291), tibia ($4,175), multiple fractures
($5,291), humerus ($5,457), femur ($8,147) and hip ($12,923). The average incremen-
tal direct cost increase in the 6-months following a fracture ranged from $5,707 for
radius fractures to $18,965 for femur fractures; observed incremental direct medi-
cal costs were $39,041 for patients with multiple fractures. Incremental observed
absenteeism costs ranged from $886 for radius fractures to $2,478 for femur frac-
tures and $3,337 for multiple fractures while incremental short term disability
costs ranged from $1,820 for radius fractures to $4,131 for hip fractures and $6,177
for multiple fractures. Multivariate adjustment yielded substantively similar re-
sults for both direct and indirect costs outcomes. CONCLUSIONS: Long bone frac-
tures are costly, both in terms of direct medical costs and lost productivity; lost
productivity represents a significant portion of the burden of long bone fractures.
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OBJECTIVES: Rheumatoid arthritis (RA) causes significant disability and health
care expenditures. Whilst RA disability RA is characterized, related cost data are
sparse. An RA disability model from a UK biologics register was mapped to the
General Practice Research Database (GPRD) (UK) and total health care costs
estimated. METHODS: Step 1: General linear modeling was used to predict HAQ
score from RA cases from the biologics register. Step 2: healthcare costs were
estimated from RA cases with one year’s observation selected from the GPRD. Costs
(GBP2011) included prescriptions, consultations and investigations from primary and
secondary care. Step 3: the association between healthcare costs and predicted HAQ
was explored using Generalized linear modeling (Poisson distribution & log-link) and
predicted costs were fitted to predicted disability. RESULTS: Step 1&hibar;Disability
was modeled using 6129 cases, (75% female, mean age 57 years (sd 12), mean
baseline HAQ 1.81 (0.72)). Six optimal HAQmodels included: gender, age, smoking,
BMI, prior DMARDs, joint replacements, systemic RA features, current DMARD
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